Literature DB >> 15367919

Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis.

Virginia De Rose1, Carlo Arduino, Nazario Cappello, Rita Piana, Paola Salmin, Marco Bardessono, Manuela Goia, Rita Padoan, Elisabetta Bignamini, Diana Costantini, Giovanna Pizzamiglio, Veronica Bennato, Carla Colombo, Annamaria Giunta, Alberto Piazza.   

Abstract

It has been suggested that genes other than CFTR could modulate the severity of lung disease in cystic fibrosis (CF). Neutrophil Fcgamma receptor II (FcgammaRII) is involved in host defense against microorganisms and in inflammatory response. We evaluated the association between genetic variability of this gene and both airway infection with Pseudomonas aeruginosa and severity of lung disease in patients with CF. We studied 167 Italian unrelated patients with CF and 50 control subjects. The distribution of FcgammaRIIA genotypes in CF patients was compared with that in control subjects and the different genotypes were related with the presence or absence of P. aeruginosa infection and markers of disease severity in CF patients. The distribution of FcgammaRIIA genotypes was not significantly different between CF patients and controls. We observed that in CF patients with the same CFTR genotype (DeltaF508/DeltaF508), those carrying the R allele of FcgammaRIIA had an increased risk of acquiring chronic P. aeruginosa infection (P=0.042, R.R.: 4.38; 95% CI: 1.17/22.4). Moreover, the frequency of R/R genotype in patients with chronic P. aeruginosa infection seems to be higher than that of control subjects and patients without chronic infection. The observation that CF patients carrying the R allele of FcgammaRIIA are at higher risk of acquiring chronic P. aeruginosa infection suggests that the FcgammaRII loci genetic variation is contributing to this infection susceptibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15367919     DOI: 10.1038/sj.ejhg.5201285

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  6 in total

1.  Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.

Authors:  Yoriko Saito; Hiroshi Kitamura; Atsushi Hijikata; Mariko Tomizawa-Murasawa; Satoshi Tanaka; Shinsuke Takagi; Naoyuki Uchida; Nahoko Suzuki; Akiko Sone; Yuho Najima; Hidetoshi Ozawa; Atsushi Wake; Shuichi Taniguchi; Leonard D Shultz; Osamu Ohara; Fumihiko Ishikawa
Journal:  Sci Transl Med       Date:  2010-02-03       Impact factor: 17.956

Review 2.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

Review 3.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

4.  The Fcgamma receptor IIA-R/R131 genotype is associated with severe sepsis in community-acquired pneumonia.

Authors:  Henrik Endeman; Marie Claire A Cornips; Jan C Grutters; Jules M van den Bosch; Hendrik J T Ruven; Heleen van Velzen-Blad; Ger T Rijkers; Douwe H Biesma
Journal:  Clin Vaccine Immunol       Date:  2009-06-03

5.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

6.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.